Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 218-225

  Cheng, An Ning ^a,b   Jiang, Shih Sheng ^a   Fan, Chi Chen ^c,d   Lo, Yu Kang ^a   Kuo, Chan Yen ^a   Chen, Chung Hsing ^a   Liu, Ying Lan ^a   Lee, Chun Chung ^a   Chen, Wei Shone ^e   Huang, Tze Sing ^a   Wang, Tao Yeuan ^c   Lee, Alan Yueh Luen ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d YUANPEI UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cdc7; Chemotherapy resistance; Oral cancer; Prognostic marker

Indexed keywords

CAMPTOTHECIN; HYDROXYUREA; MESSENGER RNA; PROTEIN CDC7; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CDC7 GENE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; MOUTH SQUAMOUS CELL CARCINOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; UPREGULATION;

CAMPTOTHECIN; CDC7; CHEMOTHERAPY RESISTANCE; CI; CONFIDENCE INTERVAL; CPT; DBF4-DEPENDENT KINASE; DDK; DDR; DNA DAMAGE RESPONSE; HAZARD RATIOS; HR; HU; HYDROXYUREA; IHC; IMMUNOHISTOCHEMISTRY; ORAL CANCER; ORAL SQUAMOUS CELL CARCINOMA; OSCC; PROGNOSTIC MARKER; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE-MEDIATED DUTP NICK-END LABELING; TUNEL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXYUREA; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RNA INTERFERENCE; SURVIVAL RATE; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; ULTRAVIOLET RAYS; UP-REGULATION;

ADENOVIRIDAE;

EID: 84880511465     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.008     Document Type: Article

References (36)

1. Labib K. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?. Genes Dev. 2010, 24:1208-1219.
2. Lei M., Tye B.K. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci 2001, 114:1447-1454.
3. Johnston L.H., Masai H., Sugino A. A Cdc7p-Dbf4p protein kinase activity is conserved from yeast to humans. Prog. Cell Cycle Res. 2000, 4:61-69.
4. Bousset K., Diffley J.F. The Cdc7 protein kinase is required for origin firing during S phase. Genes Dev. 1998, 12:480-490.
5. Duncker B.P., Brown G.W. Cdc7 kinases (DDKs) and checkpoint responses: lessons from two yeasts. Mutat. Res. 2003, 532:21-27.
6. Tsuji T., Lau E., Chiang G.G., Jiang W. The role of Dbf4/Drf1-dependent kinase Cdc7 in DNA-damage checkpoint control. Mol. Cell 2008, 32:862-869.
7. Vaziri C., Masai H. Integrating DNA replication with trans-lesion synthesis via Cdc7. Cell Cycle 2010, 9:4818-4823.
8. Lee A.Y., Chiba T., Truong L.N., Cheng A.N., Do J., Cho M.J., Chen L., Wu X. Dbf4 is direct downstream target of Ataxia telangiectasia mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint. J. Biol. Chem. 2012, 287:2531-2543.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
10. Bonte D., Lindvall C., Liu H., Dykema K., Furge K., Weinreich M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 2008, 10:920-931.
11. Montagnoli A., Moll J., Colotta F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin. Cancer Res. 2010, 16:4503-4508.
12. Kulkarni A.A., Kingsbury S.R., Tudzarova S., Hong H.K., Loddo M., Rashid M., Rodriguez-Acebes S., Prevost A.T., Ledermann J.A., Stoeber K., Williams G.H. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin. Cancer Res. 2009, 15:2417-2425.
13. Choschzick M., Lebeau A., Marx A.H., Tharun L., Terracciano L., Heilenkotter U., Jaenicke F., Bokemeyer C., Simon R., Sauter G., Schwarz J. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Hum. Pathol. 2010, 41:358-365.
14. Rodriguez-Acebes S., Proctor I., Loddo M., Wollenschlaeger A., Rashid M., Falzon M., Prevost A.T., Sainsbury R., Stoeber K., Williams G.H. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am. J. Pathol. 2010, 177:2034-2045.
15. Gonzalez M.A., Tachibana K.E., Laskey R.A., Coleman N. Control of DNA replication and its potential clinical exploitation. Nat. Rev. Cancer 2005, 5:135-141.
16. Guo B., Romero J., Kim B.J., Lee H. High levels of Cdc7 and Dbf4 proteins can arrest cell-cycle progression. Eur. J. Cell Biol. 2005, 84:927-938.
17. Montagnoli A., Tenca P., Sola F., Carpani D., Brotherton D., Albanese C., Santocanale C. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res. 2004, 64:7110-7116.
18. Koltun E.S., Tsuhako A.L., Brown D.S., Aay N., Arcalas A., Chan V., Du H., Engst S., Ferguson K., Franzini M., Galan A., Holst C.R., Huang P., Kane B., Kim M.H., Li J., Markby D., Mohan M., Noson K., Plonowski A., Richards S.J., Robertson S., Shaw K., Stott G., Stout T.J., Young J., Yu P., Zaharia C.A., Zhang W., Zhou P., Nuss J.M., Xu W., Kearney P.C. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg. Med. Chem. Lett. 2012, 22:3727-3731.
19. Montagnoli A., Valsasina B., Croci V., Menichincheri M., Rainoldi S., Marchesi V., Tibolla M., Tenca P., Brotherton D., Albanese C., Patton V., Alzani R., Ciavolella A., Sola F., Molinari A., Volpi D., Avanzi N., Fiorentini F., Cattoni M., Healy S., Ballinari D., Pesenti E., Isacchi A., Moll J., Bensimon A., Vanotti E., Santocanale C. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat. Chem. Biol. 2008, 4:357-365.
20. Ermoli A., Bargiotti A., Brasca M.G., Ciavolella A., Colombo N., Fachin G., Isacchi A., Menichincheri M., Molinari A., Montagnoli A., Pillan A., Rainoldi S., Sirtori F.R., Sola F., Thieffine S., Tibolla M., Valsasina B., Volpi D., Santocanale C., Vanotti E. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships. J. Med. Chem. 2009, 52:4380-4390.
21. Ito S., Ishii A., Kakusho N., Taniyama C., Yamazaki S., Fukatsu R., Sakaue-Sawano A., Miyawaki A., Masai H. Mechanism of cancer cell death induced by depletion of an essential replication regulator. PLoS ONE 2012, 7:e36372.
22. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in. Int. J. Cancer 1990, 80(1999):827-841.
23. Bettendorf O., Piffko J., Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?. Oral Oncol. 2004, 40:110-119.
24. Department-of-Health, (Ed.), Cancer Registry Annual Report In Taiwan, Department of Health, Taipei, Taiwan, 2009.
25. Lydiatt W.M., Shah J.P., Hoffman H.T. AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the head and neck sites task force. Head Neck 2001, 23:607-612.
26. Chang S.E., Foster S., Betts D., Marnock W.E. DOK, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. Int. J. Cancer. J. Int. Cancer 1992, 52:896-902.
27. Lu Y.C., Chen Y.J., Wang H.M., Tsai C.Y., Chen W.H., Huang Y.C., Fan K.H., Tsai C.N., Huang S.F., Kang C.J., Chang J.T., Cheng A.J. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev. Res. (Phila) 2012, 5:665-674.
28. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., Weinberg R.A., Stewart S.A., Hahn W.C. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114:241.
29. Luo J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., Sharff K.A., Luu H.H., Haydon R.C., Kinzler K.W., Vogelstein B., He T.C. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2007, 2:1236-1247.
30. Vaziri C., Saxena S., Jeon Y., Lee C., Murata K., Machida Y., Wagle N., Hwang D.S., Dutta A. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 2003, 11:997-1008.
31. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
32. Y. Hou, H.Q. Wang, Y. Ba, High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Medical oncology (Northwood, London, England) 29, 2012. pp. 3498-3503.
33. Fendri A., Kontos C.K., Khabir A., Mokdad-Gargouri R., Ardavanis A., Scorilas A. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol.: J. Int. Soc. Oncodevelop. Biol. Med. 2010, 31:391-399.
34. Iqbal J., Meyer P.N., Smith L.M., Johnson N.A., Vose J.M., Greiner T.C., Connors J.M., Staudt L.M., Rimsza L., Jaffe E., Rosenwald A., Ott G., Delabie J., Campo E., Braziel R.M., Cook J.R., Tubbs R.R., Gascoyne R.D., Armitage J.O., Weisenburger D.D., Chan W.C. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17:7785-7795.
35. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Leung S., Nielsen T., Pharoah P.D., Caldas C. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J. Pathol. 2012, 226:97-107.
36. Landi M.T., Dracheva T., Rotunno M., Figueroa J.D., Liu H., Dasgupta A., Mann F.E., Fukuoka J., Hames M., Bergen A.W., Murphy S.E., Yang P., Pesatori A.C., Consonni D., Bertazzi P.A., Wacholder S., Shih J.H., Caporaso N.E., Jen J. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008, 3:e1651.